Let’s be honest about what we’ve been arguing about for the past two years. We’ve been screaming at each other over who gets to use the “miracle” shot—the wealthy who want to drop ten pounds for a reunion, the middle class fighting with insurance companies over prior authorizations, and the internet warriors accusing everyone of vanity.
We’ve been having the wrong fight. Because while we were busy debating thigh gaps and insurance premiums, the drug was quietly doing something that should terrify and excite us in equal measure: it appears to be fighting infectious disease.
We may have accidentally built a broad-spectrum anti-infective disguised as a metabolic drug.
Here’s the staggering data: a new study out of the medical records minefield suggests that people taking GLP-1s—the class that includes Ozempic, Wegovy, and Mounjaro—were significantly less likely to be diagnosed with tuberculosis. Not just TB, but a host of serious infections. This isn’t a small blip. We’re talking about a drug class that seems to be modulating the immune system at a systemic level.
Think about what that means. We’ve spent decades building weapons against specific bugs—this antibiotic for that bacterium, this antiviral for that virus. Meanwhile, the most culturally dominant drug of the decade was apparently moonlighting as a general-purpose immune system enhancer, and we only noticed because some clever epidemiologists decided to dig through the data.
Now, before the TikTok doctors crawl out of the woodwork, let’s be precise about the mechanism. This appears to be about inflammation. GLP-1s are doing far more than suppressing appetite. They’re changing the metabolic environment of the body. They’re lowering the chronic inflammation that makes you vulnerable to pathogens in the first place.
Your immune system isn’t a weapon—it’s a garden. And metabolic health is the soil.
This reframes every argument we’ve been having about these drugs. The story isn’t “skinny drugs.” It’s not even “diabetes drugs.” The story is that we’ve been sitting on a general modulator of the human condition, and we’ve been treating it like a luxury handbag.
Here’s where the rage should kick in. Because who gets to benefit from this discovery? The study has a dirty secret buried in its methodology. It compares people taking GLP-1s to those on other diabetes drugs. And what does it find? Fewer infections. But then look at the real world.
Tuberculosis is not a disease of wealthy countries. It’s a disease of poverty, of crowded housing, of under-resourced healthcare systems, of… precisely the populations least likely to be prescribed a GLP-1.
We are developing a potential tool for diseases of poverty while pricing it like a yacht.
The obscenity is almost too perfect to be scripted. The drug class that might help the most vulnerable people on Earth is the exact drug class that has become the ultimate status symbol of the global rich. The people who need immunity support the most—because their environments are the most hostile to immune systems—are the ones who can’t get within a mile of this medication.
And don’t hand me the “skinny privilege” nonsense. This isn’t about aesthetics. This isn’t about whether your BMI warrants a prior authorization. This is about the fact that we’ve discovered a potential broad-spectrum anti-infective agent, and the free market has decided it’s a celebrity accessory.
Let’s not pretend this is an accident. This is what happens when medicine becomes a commodity and health becomes a lifestyle brand. The drugmakers know exactly what they have. Every new indication, every new study, every new association—from heart disease to sleep apnea to now infectious disease—is another patent lifeboat, another revenue stream.
But here’s the uncomfortable question that the skeptics are too polite to ask: does the pharmaceutical industry actually want to solve the problem? If we start using GLP-1s as a broad anti-infection strategy for public health, the entire business model changes. The volume would be astronomical, which would crash the prices.
We’d be talking about a class of drugs that is effectively a social determinant of health. And we can’t have that, can we? We can’t have a cheap, effective medication that could change the trajectory of global infectious disease. Not when there’s a shareholder dividend to protect.
The analogy is impossible to ignore. We spent centuries developing vaccines—the ultimate public health tool—and they worked so well that we forgot how devastating infectious disease can be. Then we watched the anti-vax movement use the internet to tear down a century of progress. And now we’re sitting on a potential breakthrough that could prevent TB and other infections not through a one-time immune training but through chronic metabolic management, and we’re going to let it languish in the hands of boutique obesity clinics?
This is not a healthcare story. This is a morality tale wrapped in a sales brochure.
We are looking at a future where the rich get chronic disease prevention and the poor get a GoFundMe.
The twist in this story is that the GLP-1 skeptics were accidentally right, but for the wrong reason. They said these drugs “suppress the immune system” and make you more vulnerable to infection. The data says the absolute opposite is true. The usual suspects have been screaming about “Ozempic face” and “Ozempic gut” while the drug was potentially making its users more resilient against tuberculosis.
Does that mean you should run out and get a prescription? No. Because the data, while compelling, is still early. The study is retrospective. The mechanism is still hazy. But the signal is so loud that ignoring it would be malpractice.
We are standing at the start of what could redefine how we think about both metabolic health and infectious disease. If the science holds up, we’re looking at a world where the treatment of chronic conditions—diabetes, obesity, metabolic syndrome—is also a de facto infectious disease prevention strategy. The silos we’ve built between “chronic care” and “infectious disease” were always artificial. This drug is telling us they’re dangerous.
Here’s what I believe, and you can screenshot this and send it to a friend who still thinks it’s just a diet drug: GLP-1s are the first glimpse of the future of medicine, where the lines between metabolism and immunity are erased. And if we let the pricing structure of the 21st century decide who gets to access that future, we’re not just failing the poor. We’re failing the species.
Because the next pandemic isn’t going to ask for your insurance card. And we need every tool we can get to make sure the people who are most vulnerable aren’t the ones left behind. But if we can’t even get a drug that treats a disease of poverty to the people living in poverty, what are we even doing?
FAQ
Q: This study is just a correlation, right? Maybe people on GLP-1s just take better care of themselves?
A: That's a fair criticism, and the study is retrospective, so it can't prove causation. But the data controls for people with type 2 diabetes comparing GLP-1 users to those on other diabetes drugs, who presumably have similar health engagement. The signal for reduced infection risk persisted. There's also a plausible biological mechanism—GLP-1s reduce systemic inflammation, and chronic inflammation is a prerequisite for many infections to take hold. It's not settled science, but it's a loud enough signal to demand rigorous prospective trials.
Q: If these drugs are so great, why not just give them to everyone?
A: Because 'give them to everyone' is a fantasy under the current system. The cost is prohibitive, the drugmakers have no incentive to drop prices when demand is insatiable, and healthcare infrastructure in high-TB-burden regions is often not equipped to handle chronic injectable therapies. The real practical implication is that we need to rethink how we price and distribute breakthrough medications. If this class genuinely prevents TB, COPD complications, and other infections, it transforms from a lifestyle drug into a public health tool. And public health tools don't work when they're locked behind a pharmacy counter with a $1,000 price tag.
Q: Aren't you just falling for big pharma's marketing by calling this a miracle drug?
A: If anything, the opposite is true. The uncomfortable truth is that the pharma giants are marketing this as a weight-loss solution because that's where the money is. The infectious disease angle is bad for their bottom line because it invites price pressure and public health scrutiny. If they were truly running a 'ghost study' campaign, they'd be suppressing the TB data, not touting it. The contrarian take here is not that the drug is good—it's that the financial incentives around it are so distorted that a potentially revolutionary public health discovery is being treated as an annoyance by the very companies that own it.